UGT92A1 Antibody
Description
Definition and Functional Role
UGT1A1 antibodies target the UDP-glucuronosyltransferase 1A1 enzyme, responsible for glucuronidating bilirubin, hormones, and drugs like irinotecan . Deficiencies in UGT1A1 activity are linked to Gilbert’s syndrome and increased toxicity risks in chemotherapy .
Pharmacogenomics
-
UGT1A1*28 Polymorphism: A 7-TA repeat variant reduces enzyme activity by 30%, increasing irinotecan toxicity (severe neutropenia: 45% vs. 18% with dose reduction) .
-
Sacituzumab Govitecan: Homozygous UGT1A128 patients had higher treatment discontinuation rates due to adverse effects (25% vs. 10% in heterozygotes) .
Drug Metabolism Studies
-
Cabotegravir Glucuronidation: UGT1A1 metabolizes 67% of this HIV integrase inhibitor, with novel variants (e.g., 454C>A) identified in diverse populations .
Technical Validation Data
-
Western Blot Performance:
-
Immunohistochemistry: Both antibodies localize UGT1A1 to hepatocytes and intestinal epithelia .
Clinical Implications
Limitations and Future Directions
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Q&A
Based on analysis of current research literature and antibody characterization data, here's a structured FAQ addressing critical research considerations for working with UDP-glucuronosyltransferase antibodies:
Advanced Research Challenges
What strategies overcome cross-reactivity in UGT isoform quantification using polyclonal antibodies?
Develop a multiplex immunoaffinity LC-MS workflow:
-
Trypsin digestion with signature peptide selection (e.g., VVMPEVSWQLGR for UGT1A9)
-
Parallel reaction monitoring for isoform-specific quantification
How to design longitudinal studies assessing UGT antibody stability in chronic exposure models?
Incorporate these controls:
-
Antibody performance metrics: Batch-to-batch EC50 variation <15%
-
Matrix effects: Spiked recovery tests in plasma vs tissue homogenates
-
Temporal validation: Monthly re-calibration against NIST reference materials
What computational approaches enhance UGT antibody validation for 3D tissue models?
Implement spatial proteomics integration:
-
Antibody-derived tagging combined with MALDI-IMS for glucuronide distribution mapping
-
Deep learning-based pattern recognition of staining intensity gradients
-
Microfluidic antibody validation chips with 12-plex UGT isoform arrays
Data Interpretation Framework
Contradiction Resolution Protocol
When facing conflicting results from UGT antibody-based assays:
-
Technical Validation
-
Biological Contextualization
-
Advanced Correlation
